LS
CORT icon

Livforsakringsbolaget Skandia’s Corcept Therapeutics CORT Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.86M Sell
114,905
-66,695
-37% -$2.49M 0.07% 133
2025
Q4 		$4.77M Buy
181,600
+106,000
+140% +$8.33M 0.19% 97
2025
Q3 		$3.33M Sell
75,600
-37,558
-33% -$2.72M 0.13% 115
2025
Q2 		$82.2M Buy
113,158
+111,158
+5,558% +$8.06M 3.58% 5
2025
Q1 		$228K Buy
+2,000
New +$122K 0.01% 361

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Livforsakringsbolaget Skandia's CORT Position: Q1 2026 in Review

Livforsakringsbolaget Skandia reduced its Corcept Therapeutics (CORT) stake by 37% in Q1 2026, selling an estimated $2.49M and leaving 114,905 shares worth $1.86M. The position accounts for 0.07% of the portfolio, ranked #133.

Livforsakringsbolaget Skandia first reported a position in CORT in Q1 2025 and has held it in 5 quarters since. The position peaked at $82.2M in Q2 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Livforsakringsbolaget Skandia held 114,905 shares of Corcept Therapeutics worth $1.86M as of Q1 2026.
  • Livforsakringsbolaget Skandia sold 66,695 Corcept Therapeutics shares in Q1 2026, an estimated $2.49M.
  • Corcept Therapeutics made up 0.07% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #133 holding.
  • Livforsakringsbolaget Skandia first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Livforsakringsbolaget Skandia's Corcept Therapeutics position peaked at $82.2M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.